Fed. Circ. Told To Nix En Banc Bid In Bristol-Myers IP Case
Teva Pharmaceuticals USA Inc. on Tuesday urged the Federal Circuit to reject Bristol-Myers Squibb Co.'s bid for en banc rehearing of a decision invalidating the patent on its hepatitis B drug...To view the full article, register now.
Already a subscriber? Click here to view full article